Tumor angiogenesis is a process where new blood vessels are formed from preexisting ones, resulting in several pathologies. Solid tumors induce angiogenesis to obtain the required nutrients and oxygen. Otherwise, tumors do not grow beyond 2 to 3 mm in diameter. Cyclooxygenase-2, an inducible enzyme important in inflammation, catalyzes the production of prostanoids from arachidonic acid. Cyclooxygenase-2 plays an important role in several cancer types, including colorectal, gastric, prostate, breast, lung, and endometrial cancer. Besides, cyclooxygenase-2 has been implicated in the progression and angiogenesis of cancers. Cyclooxygenase-2 inhibitors have been used to block angiogenesis and tumor proliferation. In this review, the recent studies related to the role of cyclooxygenase-2 in several cancer types and tumor-induced angiogenesis were compiled.
FolkmanJ.Angiogenesis in cancer, vascular, rheumatoid and other disease.Nat Med.1995; 1: 27–31.
2.
Colville-NashP.R., ScottD.L.Angiogenesis and rheumatoid arthritis; pathogenic and therapeutic implications.Ann Rheum Dis.1992; 51: 919–925.
3.
IshibashiT., MurataT., KohnoT.Peripheral choriovitreal neovascularization in proliferative diabetic retinopathy: histopathologic and ultrastructural study.Ophthalmology.1999; 213: 154–158.
4.
SueishiK., YonemitsuY., NakagawaK.Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor.Ann N Y Acad Sci.1997; 811: 311–322.
5.
LiV.W., LiW.W.Cyclosporins and angiogenesis in psoriasis.J Am Acad Dermatol.1996; 35: 1019–1021.
6.
ThurstonG., MurphyT.J., BalukP.Angiogenesis in mice with chronic airway inflammation: strain-dependent differences.Am J Pathol1998; 153: 1099–1112.
RyanC.J., LinA.M., SmallE.J.Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.Urol Oncol.2006; 24: 250–253.
10.
XieW.L., ChipmanJ.G., RobertsonD.L.Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing.Proc Natl Acad Sci V SA.1991; 88: 2692–2696.
11.
KujubuD.A., FletcherB.S., VarnumB.C.TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue.J Biol Chem.1991; 266: 12866–12872.
12.
TaketoM.M.Cyclooxygenase-2 inhibitors in tumorigenesis (part II).J Natl Cancer Inst.1998; 90: 1609–1620.
13.
KuneG.A., KuneS., WatsonL.F.Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne colorectal cancer study.Cancer Res.1998; 48: 4399–4404.
14.
IniguezM.A., RodriguezA., VolpertO.V.Cyclooxygenase-2: a therapeutic target in angiogenesis.Trends Mol Med.2003; 9: 73–78.
15.
WuG., LuoJ., RanaJ.S.Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells.Cardiovasc Res.2006; 69: 512–519.
16.
KageK., FujitaN., Oh-haraT.Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone.Biochem Biophys Res Commun.1999; 254: 259–263.
17.
SchmedtjeJ.F.J., JiY.S., LiuW.L.Hypoxia induces cyclooxygenase-2 via the NF-kB p65 transcription factor in human vascular endothelial cells.J Biol Chem.1997; 272: 601–608.
18.
TaketoM.M.Cyclooxygenase-2 inhibitors in tumorigenesis (part I).J Natl Cancer Inst.1998; 90: 1529–1536.
19.
PollardM., LuckertP.H.Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosarnine.Science.1981; 214: 558–559.
20.
WaddellW.R., LoughryR.W.Sulindac for polyposis of the colon.J Surg Oncol.1983; 24: 83–87.
21.
TsujiiM., DuBoisR.N.Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2.Cell.1995; 83: 493–501.
22.
TsujiiM., KawanoS., TsujiS.Cyclooxygenase regulates angiogenesis induced by colon cancer cells.Cell.1998; 93: 705–716.
23.
TsujiiM., KawanoS., DuBoisR.N.Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.Proc Natl Acad Sci U S A.1997; 94: 3336–3340.
24.
ChengJ., ImanishiH., AmuroY.NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines.Int J Cancer.2002; 99: 755–761.
RaoA.M., HatcherJ.F., DempseyR.J.Lipid alterations in transient forebrain ischemia: possible new mechanisms of CDP-choline neuroprotection.J Neurochem.2000; 75: 2528–2535.
27.
SmithW.L., GaravitoR.M., DeWittD.L.Prostaglandin endoperoxide H synthases (cyclooxygenases) −1 and −2.J Biol Chem.1996; 271: 33157–33160.
28.
WarnerT.D., MitchellJ.A.Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.FASEB J.2004; 18: 790–804.
29.
SmithW.L., DeWittD.L.Advances in Immunology.San Diego, CA: Academic Press; 1996.
DuboisR.N., AbramsonS.B., CroffordL.Cyclooxygenase in biology and disease.FASEB J.1998; 12: 1063–1073.
32.
ChandrasekharanN.V., DaiH., RoosK.L.COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.Proc Natl Acad Sci U S A.2002; 99: 13926–13931.
33.
PatronoC.Aspirin as an antiplatelet drug.N Engl J Med.1994; 330: 1287–1294.
34.
CroffordL.J., LipskyP.E., BrooksP., AbramsonS.B., SimonL.S., van de PutteL.B.Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.Arthritis Rheum.2000; 43: 4–13.
35.
KalgutkarA.S., ZhaoZ.Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, antiinflammatory drugs with potential utility as anti-cancer agents.Curr Drug Targets.2001; 2: 79–106.
36.
MooreB.C., SimmonsD.L.COX-2 inhibition, apoptosis, and chemoprevention by nonsteroidal anti-inflammatory drugs.Curr Med Chem.2000; 7: 1131–1144.
37.
SongX., LinH.P., JohnsonA.J.Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.J Natl Cancer Inst.2002; 94: 585–591.
38.
McGeerP.L., McGeerE.G.Inflammation of the brain in Alzheimer's disease: implications for therapy.J Leukoc Biol.1999; 65: 409–415.
39.
SmythiesJ.On the function of neuromelanin.Proc Biol Sci.1996; 263: 487–489.
40.
FunkC.D.Prostaglandins and leukotrienes: advances in eicosanoid biology.Science.2001; 294: 1871–1875.
41.
GullinoP.M.Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis.Acta Oncol.1995; 34: 439–441.
42.
NieD., LambertiM., ZacharekA.Thromboxane A2 regulation of endothelial cell migration, angiogenesis and tumor metastasis.Biochem Biophys Res Commun.2000; 267: 245–251.
43.
FormD.M., AuerbachR.PGE2 and angiogenesis.Proc Soc Exp Biol Med.1983; 172: 214–218.
44.
HanahanD., FolkmanJ.Patterns and emerging mechanisms of the angiogenic swithch during tumorigenesis.Cell.1996; 86: 353–364.
45.
ChengT., CaoW., WenR.Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat muller cells.Invest Ophthalmol Vis Sci.1998; 39: 581–591.
46.
Ben-AvP., CroffordL.J., WilderR.L.Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis.FEBS Lett.1995; 372: 83–87.
47.
HernandezG.L., VolpertO.V., IniguezM.A.Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin a: roles of the nuclear factor of activated T cells and cyclooxygenase 2.J Exp Med.2001; 193: 607–620.
48.
SalcedoR., ZhangX., YoungH.A.Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells.Blood.2003; 102: 1966–1977.
49.
JonesM.K., WangH., PeskarB.M.Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.Nat Med.1999; 5: 1348–1349.
50.
FukudaR., KellyB., SemenzaG.L.Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1.Cancer Res.2003; 63: 2330–2334.
51.
FuY.G., SungJ.J., WuK.C.Inhibition of gastric cancer-associated angiogenesis by antisense COX-2 transfectants.Cancer Lett.2005; 224: 243–252.
52.
ThomasD.W., MannonR.B., MannonP.J.Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.J Clin Invest.1998; 102: 1994–2001.
53.
DanielT.O., LiuH., MorrowJ.D.Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis.Cancer Res.1999; 59: 4574–4577.
54.
HanahanD., WeinbergR.A.The hallmarks of cancer.Cell.2000; 100: 57–70.
55.
CoussensL.M., WerbZ.Inflammation and cancer.Nature.2002; 420: 860–867.
56.
LiuC.H., ChangS.H., NarkoK.Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.J Biol Chem.2001; 276: 18563–18569.
57.
AttigaF.A., FernandezP.M., WeeraratnaA.T.Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metallo-proteinases.Cancer Res.2000; 60: 4629–4637.
58.
FarrowD.C., VaughanT.L., HanstenP.D.Use of aspirin and other nonsteroidal antiinflammatory drugs and risk of esophageal and gastric cancer.Cancer Epidemiol Biomarkers Prev.1998; 7: 97–102.
59.
Garcia-RodriguezL.A., Huerta-AlvarezC.Reduced risk of colorectal cancer among long-term users of aspirin and nonsteroidal antiinflammatory drugs.Epidemiology.2001; 12: 88–93.
60.
MorganG.Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and nonaspirin oesophageal cancers.Gut.1996; 38: 646–648.
61.
ReevesM.J., NewcombP.A., Trentham-DietzA.Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women.Cancer Epidemiol Biomarkers Prev.1996; 5: 955–960.
62.
ThunM.J.NSAID use and decreased risk of gastrointestinal cancers.Gastroenterol Clin North Am.1996; 25: 333–348.
63.
FunkhouserE.M., SharpG.B.Aspirin and reduced risk of esophageal carcinoma.Cancer.1995; 76: 1116–1119.
ThunM.J., HennekennC.H.Cancer: Principles and Practice of Oncology.Philadelphia, PA: Lippincott Williams Wilkins Press; 2001.
66.
KawamoriT., RaoC.V., SeibertK.Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.Cancer Res.1998; 58: 409–412.
67.
ReddyB.S., RaoC.V., SeibertK.Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis.Cancer Res.1996; 56: 4566–4569.
68.
SmalleyW., DuBiosR.N.Colorectal cancer and nonsteroidal anti-inflammatory drug.Adv Pharmacol.1997; 39: 1–20.
69.
YaoM., ZhouW., SanghaS.Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.Clin Cancer Res.2005; 11: 1618–1628.
70.
YaoM., KargmanS., LamE.C.Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.Cancer Res.2003; 63: 586–592.
71.
OshimaM., DinchukJ.E., KargmanS.L.Suppression of intestinal polyposis in APCD716 knockout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2).Cell.1996; 87: 803–809.
72.
JanneP.A., MayerR.J.Chemoprevention of colorectal cancer.N Engl J Med.2000; 342: 1960–1968.
73.
MizunoH., SakamotoC., MatsudaK.Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonigt delays healing in mice.Gastroenterology.1997; 112: 387–397.
74.
KargmanS., CharlesonS., CartwrightM.Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey and human gastrointestinal tracts.Gastroenterology.1996; 111: 445–454.
75.
LiH.X., ChangX.M., SongZ.J.Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.World J Gastroenterol.2003; 9: 674–677.
76.
SaukkonenK., RintahakaJ., SivulaA.Cyclooxygenase-2 and gastric carcinogenesis.APMIS.2003; 111: 915–925.
77.
OhnoR., YoshinagaK., FujitaT.Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma.Cancer.2001; 91: 1876–1881.
78.
UefujiK., IchikuraT., MochizukiH.Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas.J Surg Oncol.2001; 76: 26–30.
79.
MurataH., KawanoS., TsujiS.Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma.Am J Gastroenterol.1999; 94: 451–455.
80.
WuY.L., FuS.L., ZhangY.P.Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts.Biomed Pharmacother.2005; 59(suppl 2): 289S–292S.
81.
WuH., WuK., YaoL.Antisense inhibition of cyclooxygenase-2 reduces malignant phenotype of gastric cancer cells.Zhonghua Nei Ke Za Zhi.2002; 41: 534–537.
82.
FuS.L., WuY.L., ZhangY.P.Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer.World J Gastroenterol.2004; 10: 1971–1974.
83.
ElderD.J., HaltonD.E., HagueA.Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drug: independence from COX-2 protein expression.Clin Cancer Res.1997; 3: 1679–1683.
84.
ThunM.J., HenleyS.J., PatranoC.Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.J Natl Cancer Inst.2002; 94: 252–266.
85.
Muller-DeckerK., ReinerthG., KriegP.Prostaglandin-Hsynthase isozyme expression in normal and neoplastic skin.Int J Cancer.1999; 82: 648–656.
86.
KagouraM., ToyodaM., MatsuiC.Immunohistochemical expression of cyclooxygenase-2 in skin cancers.J Cutan Pathol.2001; 28: 298–302.
87.
BuckmanS.Y., GreshamA., HaleP.COX-2 expression is induced by UVB exposure in human skin: implication for the development of skin cancer.Carcinogenesis.1998; 19: 723–729.
TrompezinskiS., PernetI., MayouxC.Transforming growth factor-beta1 and ultraviolet A1 radiation increase production of vascular endothelial growth factor but not endothelin-1 in human dermal fibroblasts.Br J Dermatol.2000; 143: 539–545.
90.
PentlandA.P., SchogginsJ.W., ScottG.A.Reduction of UV induced skin tumors in hairless mice by selective COX-2 inhibition.Carcinogenesis.1999; 20: 1939–1944.
91.
FischerS.M., LoH.H., GordonG.B.Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.Mol Carcinog.1999; 25: 231–240.
92.
OrengoI.F., GerguisJ., PhillipsR.Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventative to UV-induced skin cancer: a study in the hairless mouse model.Arch Dermatol.2002; 138: 751–755.
93.
WilgusT.A., KokiA.T., ZweifelB.S.Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.Mol Carcinog.2003; 38: 49–58.
94.
BachelorM.A., BowdenG.T.UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression.Semin Cancer Biol.2004; 14: 131–138.
95.
KirschenbaumA., KlausnerA.P., LeeR.Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate.Urology.2000; 56: 671–676.
96.
UotilaP., ValveE., MartikainenP.Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer.Urol Res.2001; 29: 25–28.
97.
GuptaS., SrivastavaM., AhmadN.Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma.Prostate.2000; 42: 73–78.
98.
MadaanS., AbelP.D., ChaudharyK.S.Cytoplasmic induction and overexpression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment.BJU Int.2000; 86: 736–741.
99.
YoshimuraR., SanoH., MasudaC.Expression of cyclooxygenase-2 in prostate carcinoma.Cancer.2000; 89: 589–596.
100.
HwangD., ScollardD., ByrneJ.Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.J Natl Cancer Inst.1998; 90: 455–460.
101.
TjandrawinataR.R., DahiyaR., Hughes-FulfordM.Induction of cyclooxygenase-2 mRNA by prostaglandin E-2 in human prostatic carcinoma cells.Br J Cancer.1997; 75: 1111–1118.
102.
LiuX.H., KirschenbaumA., YaoS.Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.J Urol.2000; 164: 820–825.
103.
ParrettM.L., HarrisR.E., JoarderF.S.Cyclooxygenase-2 gene expression in human breast cancer.Int J Oncol.1997; 10: 503–507.
104.
DaviesG., SalterJ., HillsM.Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.Clin Cancer Res.2003; 9: 2651–2656.
105.
HarrisR.E., AlshafieG.A., Abou-IssaH.Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.Cancer Res.2000; 60: 2101–2103.
LiW., XuR.J., ZhangH.H.Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma.Int J Gynecol Cancer.2006; 16: 1673–1678.
108.
TongB.J., TanJ., TajedaL.Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptordelta in human endometrial adenocarcinoma.Neoplasia.2000; 2: 483–490.
109.
FujiwakiR., IidaK., KanasakiH.Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase.Hum Pathol.2002; 33: 213–219.
110.
FerrandinaG., LeggeF., RanellettiF.O.Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome.Cancer.2002; 95: 801–807.
111.
ToyokiH., FujimotoJ., SatoE.Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in uterine endometrial cancers.Ann Oncol.2005; 16: 51–55.
112.
YuanA., YuC.J., ShunC.T.Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.Int J Cancer.2005; 115: 545–555.
113.
WolffH., SaukkonenK., AnttilaS.Expression of cyclooxygenase-2 in human lung carcinoma.Cancer Res.1998; 58: 4997–5001.
114.
RiouxN., CastonguayA.Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398.Cancer Res.1998; 58: 5354–5360.
115.
CervelloM., FoderaaD., FlorenaA.M.Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis.World J Gastroenterol.2005; 11: 4638–4643.
116.
KogaH., SakisakaS., OhishiM.Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation.Hepatology.1999; 29: 688–689.
117.
TuckerO.N., DannenbergA.J., YangE.K.Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.Cancer Res.1999; 59: 987–990.
118.
ChanG., BoyleJ.O., YangE.K.Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.Cancer Res.1999; 59: 991–994.
119.
DenkertC., KobelM., BergerS.Expression of cyclooxygenase 2 in human malignant melanoma.Cancer Res.2001; 61: 303–308.
120.
MohammedS.I., KnappD.W., BostwickD.G.Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.Cancer Res.1999; 59: 5647–5650.
121.
PerroneG., SantiniD., VerziA.COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables.J Clin Pathol.2006; 59: 492–496.
122.
MiyataY., KogaS., KandaS.Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival.Clin Cancer Res.2003; 9: 1741–1749.
123.
Ali-FehmiR., CheM., KhalifehI.The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.Cancer.2003; 98: 1423–1429.
124.
CarmelietP., JainR.K.Angiogenesis in cancer and other diseases.Nature.2000; 407: 249–257.
125.
BergersG., BenjaminL.E.Tumorigenesis and the angiogenic switch.Nat Rev Cancer.2003; 3: 401–410.
MasferrerJ.L., LeahyK.M., KokiA.T.Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.Cancer Res.2000; 60: 1306–1311.
128.
UefujiK., IchikuraT., MochizukiH.Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer.Clin Cancer Res.2000; 6: 135–138.
129.
PrescottS.M.Is cyclooxygenase-2 the alpha and the omega in cancer?J Clin Invest.2000; 105: 1511–1513.
130.
FidlerI.J.Cancer: Principles and Practice of Oncology.Philadelphia, PA: Lippincott Raven Publishers; 1997.
131.
FerraraN., GerberH.P., LeCouterJ.The biology of VEGF and its receptors.Nat Med.2003; 9: 669–676.
NakataS., ItoK., FujimoriM.Involvement of vascular endothelia growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers.Int J Cancer.1998; 79: 179–186.
134.
GalloO., FranchiA., MagnelliL.Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.Neoplasia.2001; 3: 53–61.
135.
ZhiY.H., LiuR.S., SongM.M.Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma.World J Gastroenterol.2005; 11: 3724–3728.
136.
KogaT., ShibaharaK., KabashimaA.Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer.Hepatogastroenterology.2004; 51: 1626–1630.
137.
FosslienE.Molecular pathology of cyclooxygenase-2 in neoplasia.Ann Clin Lab Sci.2000; 30: 3–21.
138.
FosslienE.Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis.Ann Clin Lab Sci.2001; 31: 325–348.
139.
KimH.S., YoumH.R., LeeJ.S.Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer.Lung Cancer.2003; 42: 163–170.
140.
MasunagaR., KohnoH., DharD.K.Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients.Clin Cancer Res.2000; 6: 4064–4068.
141.
WuA.W., GuJ., LiZ.F.COX-2 expression and tumor angiogenesis in colorectal cancer.World J Gastroenterol.2004; 10: 2323–2326.
WuG., MannamA.P., WuJ.Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF.Am J Physiol Heart Circ Physiol.2003; 285: H2420–H2429.
144.
GatelyS., LiW.W.Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.Semin Oncol.2004; 31: 2–11.
145.
ChengA.S., ChanH.L., ToK.F.Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma.Int J Oncol.2004; 24: 853–860.
146.
CarmelietP., DorY., HerbertJ.M.Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.Nature.1998; 394: 485–490.
147.
SemenzaG.L.HIF-1 and tumor progression: pathophysiology and therapeutics.Trends Mol Med.2002; 8: S62–S67.
148.
SemenzaG.L.Targeting HIF-1 for cancer therapy.Nat Rev Cancer.2003; 3: 721–732.
149.
ChunY.S., KimM.S., ParkJ.W.Oxygen-dependent and -independent regulation of HIF-1alpha.J Korean Med Sci.2002; 17: 581–588.
150.
JonesM.K., SzaboI.L., KawanakaH.Von Hippel Lindau tumor suppressor and HIF-1 alpha: new targets of NSAIDs inhibition of hypoxiainduced angiogenesis.FASEB J.2002; 16: 264–266.
151.
LiuX.H., KirschenbaumA., LuM.Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line.J Biol Chem.2002; 277: 50081–50086.
152.
HuangS.P., WuM.S., ShunC.T.Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma.J Biomed Sci.2005; 12: 229–241.
153.
MasferrerJ.L., KokiA., SeibertK.COX-2 inhibitors. A new class of antiangiogentic agents.Ann N Y Acad Sci.1999; 889: 84–86.
